Shanghai Pharmaceuticals reports slight revenue growth, profit declines in Q1

Shanghai Pharmaceuticals Holding Co. (HKEX: 2607) announced a modest revenue increase for the first quarter of 2025, reaching CNY 70.763 billion, a 0.87% rise year-over-year. However, net profit attributable to equity holders of the listed company experienced a significant decrease of 13.56%, landing at CNY 1.333 billion. Pharmaceutical manufacturing revenue hit CNY 5.885 billion, while pharmaceutical service revenue reached CNY 64.878 billion. R&D investments remained consistent with the previous year, totaling CNY 612 million, with expenses of CNY 497 million. The company highlighted advancements in its innovative drug pipeline and the launch of new products, as well as the growth of its innovative service businesses.